Top Markets
Coin of the day
Radiopharm Theranostics Limited Radiopharm Theranostics Limited

Radiopharm Theranostics Limited

RAD
株式のランク #29689
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company,... Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
株価
$0.00846342
時価総額
$20.02M
変化(1日)
0.00%
変化(1年)
-47.56%
AU
取引 Radiopharm Theranostics Limited (RAD)

カテゴリー

Radiopharm Theranostics Limited(RAD)の配当利回りの履歴
Radiopharm Theranostics Limited(銘柄コード: RAD)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Radiopharm Theranostics Limited(RAD)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)